The "Chronic Spontaneous Urticaria Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.65% to $605.61 Friday, on what proved to be an all-around favorable ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

On an adjusted basis, Regeneron earned $8.22 per share in the first quarter, below the average analyst estimate of $8.82, ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

The indication is key as Sanofi and U.S. partner Regeneron expect sales of Dupixent to reach $22 billion by 2030. Sanofi off to a promising start in launch of Dupixent for COPD Fierce Pharma ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic spontaneous urticaria (CSU). The drug has been authorised to treat the ...

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...